Holen Sie sich die Stockscreener-App
1.98
0.00%
0.00
Schlusskurs vom Vortag:
$1.98
Offen:
$1.99
24-Stunden-Volumen:
238.67K
Relative Volume:
0.66
Marktkapitalisierung:
$191.93M
Einnahmen:
$69.56M
Nettoeinkommen (Verlust:
$-240.05M
KGV:
-0.8722
EPS:
-2.27
Netto-Cashflow:
$-121.90M
1W Leistung:
-25.28%
1M Leistung:
-36.54%
6M Leistung:
-46.92%
1J Leistung:
+173.48%
1-Tages-Spanne:
$1.96
$2.035
1-Wochen-Bereich:
$1.885
$2.70
52-Wochen-Spanne:
$0.6883
$6.04
Adc Therapeutics Sa Stock (ADCT) Company Profile
Firmenname
Adc Therapeutics Sa
Sektor
Branche
Telefon
41 21 653 02 00
Adresse
BIOPOLE, EPALINGES
Vergleichen Sie ADCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ADCT | 1.98 | 191.93M | 69.56M | -240.05M | -121.90M | -2.27 |
| VRTX | 449.69 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.75 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.89 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-04-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-11-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-08-17 | Fortgesetzt | Jefferies | Buy |
| 2021-08-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-03 | Eingeleitet | Stifel | Hold |
| 2020-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-09 | Eingeleitet | BofA/Merrill | Buy |
| 2020-06-09 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Drops By 9.7% - MarketBeat
Head to Head Comparison: ADC Therapeutics (NYSE:ADCT) & Astellas Pharma (OTCMKTS:ALPMY) - Defense World
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26% - Simply Wall St
Redmile Group, LLC Reduces Stake in ADC Therapeutics SA - GuruFocus.com
ADC Therapeutics shareholders approve capital increase - Investing.com India
Prosight Management, LP Expands Stake in ADC Therapeutics SA - GuruFocus.com
ADC Therapeutics SA (NYSE:ADCT) Q3 2024 Earnings Call Transcript - Insider Monkey
ADC Therapeutics : Guggenheim Healthcare Innovation Conference - Marketscreener.com
Analysts Set ADC Therapeutics SA (NYSE:ADCT) PT at $8.25 - Defense World
ADC Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% UpsideHere's Why - AOL
ADC Therapeutics SA (NYSE:ADCT) Receives $8.25 Average Price Target from Analysts - MarketBeat
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update - Marketscreener.com
ADC Therapeutics (NYSE:ADCT) Now Covered by Analysts at Stephens - MarketBeat
Stephens & Co. Initiates Coverage of ADC Therapeutics (ADCT) with Overweight Recommendation - MSN
ADC Therapeutics SA (ADCT) Quarterly 10-Q Report - Quartzy
ADC Therapeutics SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
ADC Therapeutics SA Reports Q3 2024: EPS of -$0.42 Misses Estima - GuruFocus.com
What To Expect From ADC Therapeutics SA (ADCT) Q3 2024 Earnings - GuruFocus.com
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting - The Malaysian Reserve
ADC Therapeutics' ZYNLONTA Shows 97% Response Rate in Lymphoma Clinical Trials | ADCT Stock News - StockTitan
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - MSN
ADC Therapeutics to Present at November 2024 Investor Conferences - BioSpace
ADC Therapeutics to Present at November Investor Conferences - The Malaysian Reserve
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - The Malaysian Reserve
ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 (PR Newswire) - Aktiellt
ADC Therapeutics (ADCT) Set to Announce Earnings on Thursday - MarketBeat
Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024 - GlobeNewswire Inc.
ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 - The Malaysian Reserve
Institutional investors own a significant stake of 32% in ADC Therapeutics SA (NYSE:ADCT) - Yahoo Finance
Global Antibody-Drug Conjugate Market Set for a ~USD 26 Billion Surge by 2030 | DelveInsight - The Malaysian Reserve
Antibody-Drug Conjugates Market to Grow at 28.4% CAGR from 2024 to 2029 - PR Newswire UK
The Manufacturers Life Insurance Company Purchases Shares of 26,938 ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA (NYSE:ADCT) Sees Large Growth in Short Interest - MarketBeat
Adc Therapeutics SA’s Shares Reel: -23.19% Quarterly Revenue Decline Amid 297.81M Market Cap - The InvestChronicle
Adc Therapeutics SA (ADCT) rating initates by Cantor Fitzgerald - Knox Daily
ADC Therapeutics SA's (NYSE:ADCT) institutional investors lost 10% over the past week but have profited from longer-term gains - Simply Wall St
Antibody Drug Conjugates Industry Report (2024-2032) - GlobeNewswire
Antibody Drug Conjugates Industry Report (2024-2032) Featuring Profiles the Top 13 PlayersADC Therapeutics, Astellas Pharma, AstraZeneca, Celldex Therapeutics, Roche & More - 24matins.uk
ADC Therapeutics : Subgroup analyses include patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients older than 65 (Form 6-K) - Marketscreener.com
Antibody Drug Conjugates Market Advancements Highlighted by Research 2024-2033 – Outlook, Overview - WhaTech
ADC Therapeutics SA (NYSE:ADCT) Shares Bought by XTX Topco Ltd - Defense World
Rhumbline Advisers Purchases Shares of 85,977 ADC Therapeutics SA (NYSE:ADCT) - Defense World
Adc Therapeutics (ADCT) Price Target Increased by 9.79% to 8.77 - MSN
Finanzdaten der Adc Therapeutics Sa-Aktie (ADCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):